Higher Prevalence Of Periodontal Disease In Rheumatoid Arthritis Patients
Over 1.3 million Americans suffer from rheumatoid arthritis (RA), a chronic, inflammatory disease of the joints. RA is a disabling condition, and can lead to long-term joint damage resulting in persistent pain and loss of function in affected areas.
Phase 3 Data Show Efficacy Of Golimumab In RA Patients Previously Treated With Anti-TNF Agents
Findings presented for the first time from a novel, randomized, double-blind, placebo-controlled Phase 3 study showed that patients with moderately-to-severely active rheumatoid arthritis (RA) who were previously treated with anti-tumor necrosis factor (TNF)-alpha agents, experienced significant improvements in signs and symptoms and physical function after receiving every four-week subcutaneous injections of golimumab (CNTO 148) 50 mg or 100 mg.
Actemra Inhibits Joint Damage And Improves Physical Function Of Patients With Rheumatoid Arthritis
Roche announced that Actemra (tocilizumab) can significantly inhibit structural damage to joints in patients with rheumatoid arthritis (RA), a critical measure of effectiveness of an RA treatment. Actemra also improved the patients' physical function after one year of therapy, leading to a better quality of life.
Molecular Response Of Cartilage To Injury Identified By Study
It's an unfortunate fact backed by studies of former professional football and soccer players: injury to joint cartilage escalates the risk of developing of osteoarthritis (OA). However, why this occurs - the details of how joint cartilage cells respond to acute trauma and how this response leads to progressive cartilage degradation - remains open to investigation.
Attorney General Martha Coakley Files Judgment Against Merck Pharmaceutical For The Company's Deceptive Marketing Of Vioxx
Attorney General Coakley's Office filed a settlement with New Jersey-based drug manufacturer Merck and Company, Inc.(Merck) resolving concerns about the company's deceptive advertising and promotion of the "Cox-2" inhibitor drug Vioxx which is a non-steroidal anti-inflammatory drug used to treat arthritis.
Ofatumumab In Subcutaneous Study In Rheumatoid Arthritis Summary: Subcutaneous Administration Of Ofatumumab Investigated In Phase I II Study
Genmab A/S (OMX: GEN) announced a Phase I/II study to evaluate a subcutaneous route of administration of ofatumumab (HuMax-CD20(R)) in rheumatoid arthritis (RA) patients, stable on methotrexate will be initiated soon. The study, which will consist of two parts and include approximately 70 patients, will be conducted by GlaxoSmithKline.
Arthritis Unnecessarily Stops Many US Diabetics Taking Needed Exercise
About half of US adults with diabetes also have arthritis, which appears to be a barrier, in addition to lack of time and being too busy with other things, because they are not sure what exercise is appropriate and they are concerned about aggravating joint pain and causing further damage.
New CDC Study Finds Arthritis Can Be A Barrier For Adults Seeking To Manage Diabetes Through Physical Activity
More than half of adults with diagnosed diabetes also have arthritis, a painful condition that can be a barrier to physical activity-an important health strategy for managing diabetes, according to a study released by the Centers for Disease Control and Prevention in today^a Euro ^2s Morbidity and Mortality Weekly Report.
Arthritis Foundation Comment On Food And Drug Administration Ongoing Safety Review Of Tumor Necrosis Factor TNF Blockers
The Food and Drug Administration (FDA) issued an early communication on June 4, 2008 regarding an ongoing safety review of Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, and Cimzia) and the possible association between the use of these medicines and the development of lymphoma and other cancers in children and young adults.
NicOx Completes Patient Enrollment In Third Naproxcinod Pivotal Phase 3 Study
NicOx S.A. (Euronext Paris: COX) announced the completion of patient enrollment in the third pivotal phase 3 clinical trial for naproxcinod, in patients with osteoarthritis of the hip (the 303 study). 810 patients have been randomized in 120 clinical centers in North America and Europe in this study, which is the final phase 3 trial in NicOx' clinical plan for the regulatory filing of naproxcinod.